The Novartis AG’s (NVS) Neutral Rating Reaffirmed at JPMorgan Chase & Co.

The Novartis AG’s (NVS) Neutral Rating Reaffirmed at JPMorgan Chase & Co.

A number of other brokerages have also recently commented on NVS. Vetr upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $79.30 target price for the company in a report on Wednesday, March 1st. Societe Generale upgraded Novartis AG from a “hold” rating to a “buy” rating and raised their target price for the company from $73.82 to $74.37 in a report on Tuesday, March 7th. BNP Paribas cut Novartis AG from a “neutral” rating to an “underperform” rating in a report on Tuesday, March 7th. Barclays PLC began coverage on Novartis AG in a report on Tuesday, March 7th. They set an “underweight” rating for the company. Finally, Cowen and Company cut Novartis AG from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $87.00 to $77.00 in a report on Wednesday, April 5th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $83.12.

Novartis AG (NYSE:NVS)‘s stock had its “neutral” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, April 18th.

Shares of Novartis AG (NYSE:NVS) opened at 77.90 on Tuesday. The stock has a market capitalization of $184.28 billion, a price-to-earnings ratio of 29.29 and a beta of 0.73. Novartis AG has a 52 week low of $66.93 and a 52 week high of $83.58. The stock’s 50 day moving average is $74.94 and its 200-day moving average is $73.33.

Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, April 25th. The company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Novartis AG had a return on equity of 15.37% and a net margin of 13.80%. The company had revenue of $11.54 billion during the quarter, compared to analysts’ expectations of $11.59 billion. During the same period last year, the business posted $1.17 EPS. Novartis AG’s revenue for the quarter was down .5% on a year-over-year basis. On average, analysts anticipate that Novartis AG will post $4.72 earnings per share for the current fiscal year. Large investors have recently bought and sold shares of the stock. Berkshire Asset Management LLC PA raised its stake in Novartis AG by 39.9% in the third quarter. Berkshire Asset Management LLC PA now owns 22,159 shares of the company’s stock worth $1,750,000 after buying an additional 6,323 shares in the last quarter. TMD & Associates Inc. raised its stake in Novartis AG by 2.0% in the third quarter. TMD & Associates Inc. now owns 39,237 shares of the company’s stock worth $3,098,000 after buying an additional 762 shares in the last quarter. Gilman Hill Asset Management LLC raised its stake in Novartis AG by 1.1% in the third quarter. Gilman Hill Asset Management LLC now owns 8,142 shares of the company’s stock worth $643,000 after buying an additional 90 shares in the last quarter. Woodley Farra Manion Portfolio Management Inc. raised its stake in Novartis AG by 0.5% in the third quarter. Woodley Farra Manion Portfolio Management Inc. now owns 324,510 shares of the company’s stock worth $25,623,000 after buying an additional 1,740 shares in the last quarter. Finally, Henderson Group PLC raised its stake in Novartis AG by 13.6% in the third quarter. Henderson Group PLC now owns 4,463 shares of the company’s stock worth $352,000 after buying an additional 534 shares in the last quarter. 9.82% of the stock is currently owned by institutional investors.

Novartis AG Company Profile Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Receive News & Ratings for Novartis AG Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novartis AG and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment